The Predictive Value of Serial 18F-FDG PET/CT for Recurrence and Survival of Locally Advanced Non-Small Cell Lung Cancer after Concurrent Chemoradiation Therapy
J. Yue,T. Xu,T. Pan,L. B. Levy,D. R. Gomez,C. Lu,R. U. Komaki,R. Mohan,Z. Liao
DOI: https://doi.org/10.1016/j.ijrobp.2015.07.1645
2015-01-01
Abstract:We examined the potential value of serial 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) scans obtained before, at week 5 during, and after treatment for predicting tumor recurrence and overall survival (OS) after concurrent chemoradiation therapy for locally advanced non-small cell lung cancer (NSCLC). Eighty-four patients with stage III NSCLC from a prospective clinical trial were evaluated by FDG PET before, during (after delivery of 40-50 Gy), and after chemoradiation therapy. PET/CT images were analyzed with microRNA target detection software and the following FDG uptake variables generated: maximum standardized uptake value [SUVmax], SUVmean, SUVpeak, metabolic tumor volume (MTV), and total lesion glycolysis (TLG). Percent changes in these variables from before to during or after treatment were also analyzed. Both the absolute values and changes in these variables were added to a clinical model (which included age, sex, race, tumor size, histology, disease stage, smoking history, receipt of induction chemotherapy, radiation technique, and total delivered dose) to assess added prediction power. Endpoints were recurrence within the planning target volume (PTV) and times to distant metastasis, disease-free survival, and OS, assessed by Cox regression analysis. Median time to recurrence within the PTV was 12 months; time to distant metastasis, 9 months; disease-free survival, 9 months; and OS, 24 months. On the pretreatment PET/CT scans, SUVmax (hazard ratio [HR] 0.938, 95% confidence interval [CI] 0.887-0.991, P=0.023) and SUVpeak (HR 0.927, 95% CI 0.870-0.988, P=0.019) of the primary tumor correlated with distant metastasis in univariate analysis but not after adjustment for clinical factors in multivariate analysis (SUVmax: HR 0.954, 95% CI, 0.899-1.012, P=0.117; SUVpeak: HR 0.944, 95% CI 0.881-0.987, P=0.106). On the mid-treatment scans, MTV and TLG of lymph nodes were associated with time to local recurrence in both univariate and multivariate analyses after adjustment for clinical factors (MTV: HR 1.027, 95% CI 1.008-1.046, P=0.005; TLG: HR 1.008, 95% CI 1.003-1.012, P<0.001). On the post-treatment PET/CT scans, no variables for primary tumor or lymph nodes, whether absolute values or percent changes were associated with clinical outcomes. Our results suggest that MTV and TLG in lymph nodes during chemoradiation therapy predicted local recurrence after concurrent chemoradiation therapy for locally advanced NSCLC. This information may help clinicians to modify treatment accordingly.